Clinical Trial Update: A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

A Phase 2 study of BIND-014 across urothelial carcinoma, cholangiocarcinoma, cervical cancer, and squamous cell carcinoma of the head and neck was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cholangiocarcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Urothelial Carcinoma

Drugs mentioned

• BIND-014 (docetaxel nanoparticle)

Snippet

Sponsor: BIND Therapeutics | Conditions: Urothelial Carcinoma, Cholangiocarcinoma | Phase 2 | Status: TERMINATED